In the 4T1 BC model, reducing the levels of the immunoregulatory cytokine Macrophage Migration Inhibitory Factor (MIF), which is frequently overexpressed in various cancers, significantly enhances ICD in vitro, particularly under serum-free conditions. This evidence concerns the gene MIF and cancer.